For our lead product, Imeglimin, a New Drug Application was submitted in Japan by Sumitomo Dainippon Pharma in July 2020. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.
View Our CandidatesOur candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View PipelineOur highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team